Literature DB >> 14627181

Neurofibromatosis type 2.

S Uppal1, A P Coatesworth.   

Abstract

Neurofibromatosis type 2 (NF2) is often not recognised as a distinct entity from peripheral neurofibromatosis. NF2 is a predominantly intracranial condition whose hallmark is bilateral vestibular schwannomas. NF2 results from a mutation in the gene named merlin, located on chromosome 22. The disease has a variable presentation, with the severe subtype having an early and rapid progression and the milder type having a later onset and a less aggressive course. The diagnosis and management of these patients present a unique challenge. There are also implications for the family members as half the cases are inherited. We discuss the genetic characteristics, clinical presentation, natural history, diagnostic criteria, investigations, screening and management of this condition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14627181

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  5 in total

1.  Regulation of Drosophila glial cell proliferation by Merlin-Hippo signaling.

Authors:  B V V G Reddy; Kenneth D Irvine
Journal:  Development       Date:  2011-12       Impact factor: 6.868

2.  Novel age-dependent targets in vestibular schwannomas.

Authors:  Amos Toren; Juergen K Reichardt; Ali Andalibi; Nancy Ya-Hsuan Hsu; Joni Doherty; William Slattery; Ruty Mehrian-Shai
Journal:  Hum Genomics       Date:  2014-06-30       Impact factor: 4.639

3.  Neurofibromatosis type 2 patient presenting with medulloblastoma.

Authors:  Jan Kalimullah; Abdul Malik Amir Humza Sohail; Rai Dilawar Shahjehan; Sabeehuddin Siddique; Muhammad Ehsan Bari
Journal:  Surg Neurol Int       Date:  2015-10-07

4.  Does GATA3 act in tissue-specific pathways? A meta-analysis-based approach.

Authors:  Brian J Wilson
Journal:  J Carcinog       Date:  2008

Review 5.  The Role of the JC Virus in Central Nervous System Tumorigenesis.

Authors:  Nicholas Ahye; Anna Bellizzi; Dana May; Hassen S Wollebo
Journal:  Int J Mol Sci       Date:  2020-08-28       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.